Patient - Centered Communication Tool Feasible for Seniors With Acute Myeloid Leukemia
Patients, caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 22, 2022 Category: Cancer & Oncology Tags: Oncology, Geriatrics, Journal, Source Type: news

Patient-Centered Communication Tool Feasible for Seniors With Acute Myeloid Leukemia
THURSDAY, Dec. 22, 2022 -- Incorporation of an innovative patient-centered communication tool (UR-GOAL tool) is feasible for older adults with newly diagnosed acute myeloid leukemia (AML), according to study published online Dec. 19 in Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 22, 2022 Category: Pharmaceuticals Source Type: news

Single - Tube Multiparametric Flow Cytometry Predicts Treatment Response in Leukemia
Multiparametric flow cytometry has excellent prediction for survival among patients with B - cell acute lymphoblastic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 21, 2022 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news

Single-Tube Multiparametric Flow Cytometry Predicts Treatment Response in Leukemia
WEDNESDAY, Dec. 21, 2022 -- A single-tube eight-color multiparametric flow cytometry (MFC) panel has good sensitivity for minimal/measurable residual disease (MRD) and excellent prediction for survival among patients with B-cell acute lymphoblastic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2022 Category: Pharmaceuticals Source Type: news

Mayo Clinic Q & amp;A podcast: Advancing treatments for acute myeloid leukemia
Acute myeloid leukemia (AML), also called acute myelogenous leukemia, is a cancer of the blood and bone marrow, the spongy tissue inside bones where blood cells are made. The disease progresses rapidly, affecting a group of white blood cells called myeloid cells, which normally develop into mature red blood cells, white blood cells and platelets.  "There are acute and chronic leukemias, explains Dr. James Foran, an oncologist at Mayo Clinic. "The chronic ones tend to happen… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 20, 2022 Category: Databases & Libraries Source Type: news

Immuneel's CAR-T cell therapy reports positive in early phase-2 trials in India
The early results from the IMAGINE study were based on the first 10 patients of the planned 24 patients to be enrolled.Both adult and children with acute leukemia as well as lymphoma patients post median 2 lines of treatment, including in post-transplant settings were enrolled. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 20, 2022 Category: Pharmaceuticals Source Type: news

CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib
The second-generation Bruton ' s tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study in patients with chronic lymphocytic leukemia (CLL) .MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 19, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Dec. 19, 2022 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Rigel Pharmaceuticals as one of two specialty pharmacies in a limited distribution network for REZLIDHIATM (olutasidenib), which is indicated for... (Source: McKesson News)
Source: McKesson News - December 19, 2022 Category: Information Technology Source Type: news

Mum-of-two experienced ‘agonising chest pains’ prior to leukaemia diagnosis - other signs
Luckily the English teacher is back to "living a full and active life" following a life-saving stem cell transplant. (Source: Daily Express - Health)
Source: Daily Express - Health - December 18, 2022 Category: Consumer Health News Source Type: news

STORM Therapeutics announces closing of USD $30M Series B financing
Proceeds will advance STORM's potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias Financing will further expand STORM's novel discovery platform to create additional products targeting RNA modification ... Biopharmaceuticals, Venture Capital STORM Therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 14, 2022 Category: Pharmaceuticals Source Type: news

Gene editing technology for treatment-resistant cancer could be a 'scientific layup' to treat other diseases
For the first time, a new gene editing technology called base editing was used to modify immune cells and successfully treat a teen with treatment-resistant leukemia. A month afterward, 13-year-old Alyssa was in remission, and she continues to do well several months later. (Source: CNN.com - Health)
Source: CNN.com - Health - December 13, 2022 Category: Consumer Health News Source Type: news

Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Roche presents new and updated data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
Updated data from the phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large B-cell lymphoma (DLBCL)1Patients receivingPolivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes, during and after fixed-duration treatment, to those receiving the current standard-of-care, withsuperiorprogression-free survival2Basel, 12 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new and updated data for its first-in-class anti-CD79b antibody-drug conjugate Polivy ® ...
Source: Roche Media News - December 12, 2022 Category: Pharmaceuticals Source Type: news

Roche presents new and updated data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
Updated data from the phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large B-cell lymphoma (DLBCL)1Patients receivingPolivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes, during and after fixed-duration treatment, to those receiving the current standard-of-care, withsuperiorprogression-free survival2Basel, 12 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new and updated data for its first-in-class anti-CD79b antibody-drug conjugate Polivy ® ...
Source: Roche Investor Update - December 12, 2022 Category: Pharmaceuticals Source Type: news